People's Livelihood and Drug Safety

Chinese Journal of Pharmacovigilance ›› 2012, Vol. 9 ›› Issue (6): 338-339.

• Orginal Article • Previous Articles Next Articles

People's Livelihood and Drug Safety

LIU Jia¹, LI Guo-qing^{2, *}

1 Center for Drug Reevaluation, SFDA, Beijing 100045, China;
2 State Food and Drug Administration, Beijing 100053, China

Received:2012-03-08 Online:2012-06-10 Published:2015-08-10

Abstract

Abstract: Medicine is an important tool for protecting public health.So the drug safety is always concerned with a matter of the people's livelihood. As an essential content of the basic health system, drug safety protecting is one of the primary subjects in improving people's livelihood. This article analyzes the definition of people's livelihood and drug safety, discusses the relationship between them and provides some advice and reference on drug safety administration.

Key words: people's livelihood, drug safety, definition, relationship

LIU Jia, LI Guo-qing. People's Livelihood and Drug Safety[J]. Chinese Journal of Pharmacovigilance, 2012, 9(6): 338-339.

[1]	MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
[2]	WANG Xiang, SUN Shuai, WANG Xinguo, NIU Liying. Quantitative transfer relationships of Rubia yunnanensis Diels formula granules based on standard decoctions [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 891-898.
[3]	LIU Jingjing, DAI Zhong, YANG Jianbo, WANG Ying, XU Beilei, LIU Yue, WANG Qi, MA Shuangcheng. Spectrum-fect relationship of Ginseng Radix et Rhizoma Rubra and Polygonum Multiflorum Radix Preparata medicinal pair in protection of nerve cells [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 623-628.
[4]	LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping. Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
[5]	LIN Ni, YE Qian, GENG Xingchao, WANG Xue, JIN Hongtao, WEN Hairuo. Genotoxicity of 5-hydroxymethylfurfural and its dipolymer and metabolite [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 157-162.
[6]	JIANG Jiandong. Development and clinical safety of paediatric medicines in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 1-6.
[7]	WANG Juli, ZHANG Xiaomeng, ZHANG Bing, LYU Jintao. Safety of medications for cardiovascular diseases in community clinics [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 744-748.
[8]	WANG Chunqing, ZHANG Yuanyuan, LI Qian, DU Lina, JIN Yiguang. Research progress on pharmacological effect and structure-activity relationship of common cannabinoid compounds [J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1388-1392.
[9]	HUANG Liting, TANG Zaixiang, BAI Lu, SHI Guanhong, JIANG Yiguo. Adverse reactions of benzodiazepines based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1223-1227.
[10]	WU Yingqi, ZHU Ting, TONG Tong, LI Min, SHEN Aizong. Factors related to ADR/ADE of albumin bound paclitaxel [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1123-1127.
[11]	WANG Wen, LIU Mei, HE Qiao, TIAN Chunhua, SONG Haibo, WANG Tao, TAN Jing, REN Yan, GAO Pei, PENG Xiaoxia, WEN Zehuai, SHU Xiaochen, ZOU Kang, SHEN Chuanyong, SUN Xin. Expert consensus on design and statistical analysis to evaluate drug safety using routinely collected health data [J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 7-12.
[12]	ZHANG Dan, LYU Jintao, SONG Haibo, ZHANG Bing, JIN Yongnan, SA Rina, ZHANG Xiaomeng, LIN Zhijian. Drug Risk Communication among Drug Regulatory Agencies in the European Union, the United States and Asia [J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 845-849.
[13]	MENG Ruogu, ZHUO Lin, QIAO Rui, LIU Yuqiang, SUN Feng, ZHAN Siyan. Application Values of Real-World Evidence in Post-Marketing Surveillances and Evaluation for Drug Safety [J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 624-627.
[14]	LI Jiayi, GE Feilin, CAO Junling, ZHOU Xiaochun, GAO Yunjuan, MU Guangdi, ZHAO Xu, CAO Boya, GUO Yuming. Clinical Characteristics and Rationality of Drug Usage in Antibiotic Agents Related Liver Injury [J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1020-1024.
[15]	XUE Xue, JIN Xinyan, LU Chunli, DAI Ning, LIU Jianping. Application of Real-World Study Designs in Post-Marketing Evaluation of Drug Safety [J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1025-1028.

People's Livelihood and Drug Safety

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics